Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Standard Medicines
Drugs
Locations
Clinical Specialty
1001-1020 of 1,782 trials

Gastrointestinal Stromal Tumors: Imatinib Treatment Study

We are exploring whether continuing or stopping imatinib treatment after 10 years benefits patients with advanced GISTs. The study looks at health outcomes like survival rates and quality of life.

Locally Advanced or Metastatic Gastrointestinal Stromal Tumors>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Mantle Cell Lymphoma: Ibrutinib and Venetoclax Study

We are studying the effects of Ibrutinib alone and in combination with Venetoclax in patients with untreated mantle cell lymphoma. The goal is to see how well these treatments reduce disease levels in the body.

Untreated Mantle Cell Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Infectious Pulmonary Endotheliopathy: Iloprost Infusion Study

We are investigating whether a continuous infusion of iloprost can help reduce the risk of death in mechanically ventilated patients with infectious pulmonary issues. This study compares the treatment to a placebo to assess its effectiveness.

Respiratory FailureInfectious Pulmonary Endotheliopathy>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesInternal MedicinePulmonology

Protecting Children from Radiation-Induced Hypothyroidism

We are studying whether TSH suppression during radiation therapy can lower the risk of hypothyroidism in children with medulloblastoma and lymphomas. This trial also examines any changes in thyroid tissue after treatment.

Hodgkin and Non-Hodgkin LymphomaMedulloblastoma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesEndocrinologyOncology

IgA Nephropathy: Hydroxychloroquine Study

We are studying whether Hydroxychloroquine can help slow kidney function decline in patients with IgA Nephropathy. This trial focuses on those with high levels of protein in their urine despite current treatments.

IgA Nephropathy>2 yearsConfirmation phase (III)Standard MedicinesInternal MedicineNephrology

Sickle Cell Disease and β-Thalassemia: CTX001 Treatment Study

We are studying the long-term safety and effectiveness of a new CRISPR-based treatment for patients with β-thalassemia or severe sickle cell disease. This research aims to understand how well the treatment works over time.

Sickle Cell DiseaseTransfusion Dependent ThalassemiaConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematology

Bladder Cancer: Neoadjuvant Chemotherapy Study

We are testing whether bladder instillation of neoadjuvant chemotherapy can help prevent recurrence in patients with non-muscle-invasive bladder cancer. This study compares it to standard treatment to assess effectiveness and side effects.

Non-muscle invasive bladder cancer>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesOncologyUrology

Anticoagulant Treatments for Intra-Cardiac Thrombus: The ARGONAUT Trial

We are comparing a new direct oral anticoagulant with a standard vitamin K antagonist in patients with intra-cardiac thrombus. The goal is to see which treatment better reduces complications and promotes thrombus regression.

Intracardiac Thrombus>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyInternal Medicine

BCR-ABL1+ Chronic Myeloid Leukemia: Asciminib Treatment Study

We are studying Asciminib, alone or with Nilotinib, for adults with BCR-ABL1+ Chronic Myeloid Leukemia. The goal is to see if this treatment helps achieve better disease control and improves quality of life.

Chronic Myeloid Leukemia>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteHematologyOncology

Systemic Juvenile Idiopathic Arthritis: Sarilumab Study

We are testing the medication sarilumab in children and adolescents with systemic juvenile idiopathic arthritis to find the best dose and understand its effects and safety.

Systemic Juvenile Idiopathic Arthritis (sJIA)3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemotePediatricsRheumatology

Colon Cancer: HIPEC with Mitomycin-C Study

We are investigating whether adding a special chemotherapy during surgery helps prevent cancer recurrence in patients with colon cancer that has spread to the abdomen. This study compares outcomes for those receiving this treatment versus standard care.

Peritoneal Metastases of Colorectal Cancer>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesOncology

Pain Relief for First-Degree Perineal Tears: Emla Cream vs. Injection

We are comparing a topical cream to an injection for pain relief in women with first-degree perineal tears after childbirth. The goal is to see which method provides better comfort during and after the repair.

First-Degree Perineal Laceration6-12 monthsMonitoring phase (IV)No PlaceboStandard MedicinesGynecology and Obstetrics

Pemigatinib for Solid Tumors with FGFR Alterations

We are studying whether pemigatinib can help patients with recurrent or metastatic solid tumors that have a specific gene change. The trial aims to assess its effects on tumor growth and overall patient health.

Recurrent or Metastatic Solid Cancer with FGFR Alterations>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Pancreatic Cancer: CEB-01 Treatment Study

We are exploring a new treatment called CEB-01 for people with pancreatic cancer to see how safe it is and if it may help improve their condition.

Pancreatic Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Septic Shock: Landiolol Infusion Study

We are investigating whether Landiolol can improve blood flow and heart function in patients with septic shock. This study compares its effects to standard treatments for managing rapid heart rates.

Microcirculatory Abnormalities in Septic Shock>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyInfectious Diseases

Tuberculosis Treatment: Tedizolid vs. Linezolide

We are studying how well tedizolid works compared to linezolide in reducing tuberculosis bacteria in patients. This trial aims to find out which treatment may be more effective in the first days of therapy.

Multidrug-Resistant TuberculosisEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesInternal Medicine

HIV Control: Pomalidomide Study

We are studying whether pomalidomide can help control HIV in people on treatment who take a break from their medication. The trial also examines its effects on the immune system and HIV persistence.

HIV-1 Infection3-6 monthsSafety phase (I)Efficacy phase (II)11-15 visitsStandard MedicinesInfectious DiseasesInternal Medicine

Pancreatic Exocrine Insufficiency: Creon® Therapy

We are studying how well Creon® helps patients with pancreatic exocrine insufficiency after surgery. The goal is to see if it improves symptoms and nutritional health.

Pancreatic Exocrine Insufficiency6-12 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyInternal Medicine

Squamous Cell Carcinoma of the Penis: Lymphadenectomy and Chemotherapy Study

We are studying a treatment combining surgery and chemotherapy for patients with inguinal lymph node metastases. The goal is to see if this approach improves survival and reduces the chance of cancer returning.

Penis Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Heart Attack Treatment: Cangrelor and Bivalirudin

We are studying a new combination of medications for patients with heart attacks in critical condition. The goal is to see if this treatment can prevent blood clots while keeping bleeding risks low.

Cardiogenic Shock>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCardiologyInternal Medicine